ArticlePLOS global public health2026
High prevalence and multidrug resistance of Methicillin-resistant Staphylococcus aureus at a provincial referral hospital in Zambia: A 5-year retrospective study.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) poses challenges in healthcare settings, contributing to antimicrobial resistance and complicating treatment of staphylococcal infections. In resource-limited settings such as Zambia, staphylococcal infections are treated empirically with clindamycin or co-trimoxazole due to limited susceptibility testing. However, MRSA and multidrug resistance are reducing treatment effectiveness. This study aimed to determine the prevalence and antimicrobial susceptibility of MRSA at Mansa General Hospital, Zambia. A retrospective cross-sectional study was conducted on 266 clinical S. aureus isolates from 2020-2024. Bacterial identification was performed using microbiological methods (Mannitol Salt Agar, catalase, coagulase, DNase tests). MRSA detection and antimicrobial susceptibility testing (AST) using the Kirby-Bauer disk diffusion- method with cefoxitin (30 µg) as a surrogate marker, interpreted according to CLSI M100 34th Edition guidelines. Multivariable logistic regression identified factors associated with MRSA. Among 266 S. aureus isolates, the overall MRSA prevalence was 31.6% (84/266). MRSA demonstrated significantly lower susceptibility than MSSA to non-beta-lactam antibiotics: clindamycin (46.2% vs. 67.7%), erythromycin (50.0% vs. 79.5%), ciprofloxacin (58.2% vs. 91.4%), and tetracycline (58.3% vs. 81.9%). Chloramphenicol (86.5% vs. 100%) and linezolid (81.8% vs. 97.9%) retained activity. MDR prevalence was 28.6% (76/266), with higher MDR (57.1%, 48/84) than MSSA (15.4%, 28/182). Older age was independently associated with MRSA: adults aged 45-59 years (AOR 2.77; 95% CI 1.09-7.01; p = 0.032) and ≥60 years (AOR 4.53; 95% CI 1.45-14.1; p = 0.009) had higher odds compared to children. Sex, patient type and specimen source were not significant predictors. This study highlights the high prevalence of MRSA at Mansa General Hospital, reduced susceptibility to used oral antibiotics and a burden of multidrug resistance. Empirical use of clindamycin and erythromycin for suspected staphylococcal skin and soft tissue infections should be reconsidered and guided by local antimicrobial susceptibility whenever available. Continued local surveillance and multicenter studies are needed to inform empirical treatment guidelines across Zambia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.